By Sheeba M. | April 20, 2026
On 4/20, Cannabis Investors Get a Tax Relief Surprise Hidden in the Rescheduling Plan
April 20 has long been a symbolic date for the cannabis industry. But in 2026, there’s a concrete financial reason for investors to celebrate beyond the symbolism. Buried in Executive Order 14067 signed by President Trump last December — directing the Attorney General to reschedule cannabis from Schedule I to Schedule III — is a provision that could reshape the economics of every major multi-state operator.
Section 280E: The Hidden Tax Hammer
Under current federal law, cannabis remains classified as a Schedule I controlled substance — the same classification as heroin and LSD. That classification has enabled one of the most punishing tax regimes in American business: Section 280E of the Internal Revenue Code.
Section 280E prevents cannabis businesses from deducting ordinary and necessary business expenses — ordinary deductions like rent, payroll, and utilities that every other legal business takes for granted. For MSOs operating in multiple states with thin margins, this has meant effective tax rates of 40–70% on gross profits, severely hampering profitability and growth capital allocation.
Rescheduling cannabis to Schedule III would strip away Section 280E’s applicability, allowing MSOs to take standard business deductions. For a company like Cresco Labs or Green Thumb Industries, this could translate to millions in deferred tax relief flowing directly to bottom-line earnings — potentially compressing valuation multiples and making these stocks significantly more attractive relative to legal, non-cannabis operators.
The Rescheduling Timeline: Don’t Count on Quick Relief
While the Executive Order directs the Attorney General to engage in rulemaking through the DEA and Department of Health and Human Services, legal experts caution that the pathway to actual relief is far from immediate. The DEA can use either an expedited process or traditional notice-and-comment rulemaking — and either path will likely face litigation. Barring challenges, an expedited process could take six months or more, while standard rulemaking can stretch for years.
The Trump administration has grown impatient with the pace. During an Oval Office event on Saturday, President Trump was overheard asking officials directly: “You know, they’re slow-walking me on rescheduling. You’re going to get it done, right, please?” — a public signal that the delay is reaching the highest levels of government.
What Investors Should Do Now
While the tax relief is not immediate, the direction of travel is clear. Canopy Growth and Tilray Brands — both Canadian LPs with significant U.S. market exposure — stand to benefit from both the rescheduling momentum and the competitive advantage relief from 280E would bring to their American operations.
For now, investors should watch for any signals from the DEA regarding expedited rulemaking timelines, and monitor companies that are actively building out infrastructure in advance of federal clarity. Trulieve, Verano Holdings, and Curaleaf are all well-positioned to convert rescheduling into dramatic earnings-per-share improvement once 280E is lifted.
On this 4/20, the tax man might finally become an investor’s best friend.
Sources
- Reuters — Tax relief on the horizon: How federal rescheduling could reshape cannabis business taxes (April 20, 2026)
- Marijuana Moment — Trump Complains DOJ Is ‘Slow-Walking’ Marijuana Rescheduling (April 2026)
Track cannabis stocks with the Weedstock Real-Time Tracker